Related Experiment Video

Updated: Jul 10, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Genetic determinants of the efficiency of climatotherapy in patients with chronic heart failure

D V Kovlen1, A Yu Tishakov, O S Glotov

  • 1Department of Balneology and Physiotherapy, S. M. Kirov Military Medical Academy, St. Petersburg. denis.kovlen@mail.ru

Bulletin of Experimental Biology and Medicine
|November 21, 2007
PubMed

Insights

Climatotherapy effectiveness for chronic heart failure patients depends on specific gene variations. Certain gene combinations, like Ca(2+)-ATPase and beta1-adrenoceptor, showed additive effects for improved heart function.

Area of Science:

  • Cardiology
  • Genetics
  • Environmental Medicine

Background:

  • Chronic heart failure (CHF) affects millions globally, necessitating diverse treatment strategies.
  • Climatotherapy, a non-pharmacological approach, shows promise in managing CHF symptoms.
  • Genetic factors are increasingly recognized for their role in individual treatment responses.

Purpose of the Study:

  • To investigate the influence of specific gene polymorphisms on climatotherapy effectiveness in CHF patients (functional classes 0-II).
  • To explore potential gene-gene interactions in mediating the cardiotonic effects of climatotherapy.

Main Methods:

  • Genotyping of Ca(2+)-ATPase, phospholamban, beta1-adrenoceptor, and insulin-like growth factor 1 genes in CHF patients.
  • Assessment of climatotherapy effectiveness based on clinical outcomes.
  • Statistical analysis to determine gene polymorphism associations and interactions.

Main Results:

  • Climatotherapy effectiveness varied significantly based on the polymorphisms of the studied genes.
  • Optimal outcomes were observed in patients with specific genotypes: GG for Ca(2+)-ATPase, GT for phospholamban, ArgGly for beta1-adrenoceptor, and 19/19 for IGF-1.
  • An additive interaction between Ca(2+)-ATPase and beta1-adrenoceptor gene polymorphisms was identified, enhancing the cardiotonic effect.

Conclusions:

  • Gene polymorphisms play a crucial role in determining individual responses to climatotherapy in CHF.
  • Targeting patients with specific favorable genotypes may optimize climatotherapy benefits.
  • The additive interaction of Ca(2+)-ATPase and beta1-adrenoceptor genes highlights a potential pathway for enhanced cardiotonic effects through climatotherapy.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...